5-Bromo-2-((2-chloro-4-iodophenyl)amino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide 5-溴-2-((2-氯-4-碘苯基)氨基)-N-(环丙基甲氧基)-3,4-二氟苯甲酰胺
CAS 212631-67-9 MFCD16038897
化学结构图
SMILES: O=C(NOCC1CC1)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1Cl
化学属性
| Mol. Weight | 557.55 |
|---|---|
| Mol. Formula | C17H13BrClF2IN2O2 |
| Appearance | Solid powder |
| Solubility | Soluble in DMSO |
别名和识别编码
| Synonym | 5-Bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-benzamide 5-Bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-benzamide PF-1529483 PF-3011370 UK-287074 PD184161; PD 184161; PD184161; PF1529483 PF3011370 UK287074. PF-1529483 PF-3011370 UK-287074 |
|---|---|
| MDL Number | MFCD16038897 |
| CAS Number | 212631-67-9 |
| Chemical Name | 5-Bromo-2-((2-chloro-4-iodophenyl)amino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide |
| PubChem Substance ID | 329823704 |
| Chemical Name Translation | 5-溴-2-((2-氯-4-碘苯基)氨基)-N-(环丙基甲氧基)-3,4-二氟苯甲酰胺 |
| Formula | C17H13BrClF2IN2O2 |
| IUPAC Name | 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide |
| InChIKey | VJNZMSLGVUSPCF-UHFFFAOYSA-N |
| InChI | InChI=1S/C17H13BrClF2IN2O2/c18-11-6-10(17(25)24-26-7-8-1-2-8)16(15(21)14(11)20)23-13-4-3-9(22)5-12(13)19/h3-6,8,23H,1-2,7H2,(H,24,25) |
| Canonical SMILES | O=C(NOCC1CC1)C2=CC(Br)=C(F)C(F)=C2NC3=CC=C(I)C=C3Cl |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Kinase/Phosphatase Biology, Mitogen-Activated Protein Kinase Kinase (MAPKK), P-PH, Pfizer Compounds, Serine/Threonine Kinase Biology, Serine/Threonine Kinase Inhibitors, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
- Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience, Kinase/Phosphatase Biology, Mitogen-Activated Protein Kinase Kinase (MAPKK), P, Pfizer Compounds, Serine/Threonine Kinase Biology, Serine/Threonine Kinase Inhibitors
产品应用
- PD184161 is an orally-active MEK inhibitor. PD184161 inhibited MEK activity (IC50 = 10-100 nM) in a time- and concentration-dependent manner more effectively than PD098059 or U0126. PD184161 inhibited cell proliferation and induced apoptosis at concentrations of > or = 1.0 microM in a time- and concentration-dependent manner. PD184161 has antitumor effects in HCC in vitro and in vivo that appear to correlate with suppression of MEK activity. PD184161 is unable to suppress MEK activity in HCC xenografts in the long term.
相关文献及参考
- Yip-Schneider, M.T., et al., Resistance to mitogen-activated protein kinase kinse (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 329 , 1063-1070, (2009)
- Choi, J., et al., The effect of doxorubicin on MEK-ERK signaling predicts its efficacyin HCC. J. Surg. Res. 150 , 219-226, (2008)
- Duman, C.H., et al., A role for MAP kinase signaling in hehavioral models of depression and antidepressant treatment. Biol. Psychiatry 61 , 661-670, (2007)
安全信息
GHS Symbol
- P273 Avoid release to the environment. 避免释放到环境中。
- H400 Verytoxictoaquaticlife 对水生生物毒性非常大。
